MPC3100 Property

Boiling point:

772.4±70.0 °C(Predicted)

Density 

1.77±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

Soluble in DMSO

form 

Powder

pka

13.95±0.20(Predicted)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P271Use only outdoors or in a well-ventilated area.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P312Call a POISON CENTER or doctor/physician if you feel unwell.

P321Specific treatment (see … on this label).

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P337+P313IF eye irritation persists: Get medical advice/attention.

P403+P233Store in a well-ventilated place. Keep container tightly closed.

P405Store locked up.

P501Dispose of contents/container to..…

MPC3100 Chemical Properties,Usage,Production

Uses

MPC-3100 is a recently discovered fully synthetic purine-based Hsp90 Inhibitor exhibiting anticancer properties

Biological Activity

mpc-3100 is a purine-based inhibitor of hsp90 with ic50 value of 60nm [1].mpc-3100 targets the n-terminal atp-binding site of hsp90 and blocks the activity of atpase. in the her2-luciferase degradation assay, mpc-3100 reduces this client protein of hsp90 with ic50 value of 60nm. in hct-116 cell lines, mpc-3100 inhibits cell proliferation with ic50 value of 540nm. besides that, mpc-3100 shows a broad spectrum anti-proliferative activity against various cancer cell lines, such as nci-n87 and du-145. mpc-3100 also inhibits tumor growth in the nci-n87 gastric cancer xenograft mode. moreover, pk studies show that mpc-3100 displays a superior oral pk profile, good overall exposure and a reasonable hepatic clearance rate. phase i clinical studies demonstrate mpc-3100 is safe and tolerated when administered at doses below 600 mg per day [1].

References

[1] kim sh, bajji a, tangallapally r, markovitz b, trovato r, shenderovich m, baichwal v, bartel p, cimbora d, mckinnon r, robinson r, papac d, wettstein d, carlson r, yager km. discovery of (2s)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9h-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (mpc-3100), a purine-based hsp90 inhibitor. j med chem. 2012 sep 13;55(17):7480-501.